Poly Medicure (531768) Q4 05/06 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 05/06 earnings summary
2 Nov, 2026Executive summary
FY 2005-06 net sales reached Rs 7,043.41 lakh and net profit Rs 717.53 lakh; production hit a record 1,143.41 lakh medical disposables.
Export reach exceeded 45 countries; exports contributed 84.4% of turnover amid pricing pressure and rupee appreciation.
Financial highlights
Net sales rose 10.55% YoY to Rs 7,043.41 lakh; total revenue was Rs 7,093.86 lakh versus Rs 6,425.60 lakh.
Profit before interest, depreciation and taxes was Rs 1,375.87 lakh; PBT rose 11.37% to Rs 851.62 lakh and PAT rose 18.09% to Rs 717.53 lakh.
EPS was Rs 13.29; proposed dividend was 20%, or Rs 2 per equity share.
Outlook and guidance
FY 2006-07 operations expected to benefit from added production capacity; outlook described as reasonably positive.
Blood bag expansion was completed; IV cannula capacity expansion and a needle manufacturing plant were progressing, with completion expected in Q3 and Q4 FY 2006-07, respectively.
Hardwar facility’s first phase was expected by December 2006; technically advanced products were planned for domestic and overseas markets.
Latest events from Poly Medicure
- Acquisition-led revenue growth and a European rebound faced pressure on consolidated margins.531768
Q2 26/27 - Commercial production began in Apr 1997 after delays; FY turnover and PBT were nil.531768Q4 96/97
- Revenue and production grew, but depreciation drove a FY99 net loss.531768Q4 98/99
- First-period profit was modest as depressed markets and blood-bag restrictions curtailed performance.531768Q4 97/98
- Profit returned as production grew 77.10% and export turnover nearly doubled.531768Q4 99/00
- Higher production lifted profit, while commissioned expansion set up the next growth phase.531768Q4 01/02
- FY04 growth and capacity expansion advanced, with exports at 83.8% of sales.531768Q4 03/04
- Profit and exports surged as capacity expansion and Egypt production plans advanced.531768Q4 02/03
- Sales rose 31.2%, PAT climbed 40.4%, and exports reached 86.4% of sales.531768Q4 04/05